Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy
Abstract As the non-steroidal anti-inflammatory drugs (NSAIDs) are typically used in the treatment of chronic conditions, the incidence of NSAID-induced enteropathy is increasing. Given the challenges associated with discontinuing NSAIDs, effective preventive and treatment strategies are crucial. We...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-78581-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850062159565815808 |
|---|---|
| author | Hyun Jung Lee Ji Wook Moon Seong-Joon Koh Jong Pil Im Byeong Gwan Kim Joo Sung Kim |
| author_facet | Hyun Jung Lee Ji Wook Moon Seong-Joon Koh Jong Pil Im Byeong Gwan Kim Joo Sung Kim |
| author_sort | Hyun Jung Lee |
| collection | DOAJ |
| description | Abstract As the non-steroidal anti-inflammatory drugs (NSAIDs) are typically used in the treatment of chronic conditions, the incidence of NSAID-induced enteropathy is increasing. Given the challenges associated with discontinuing NSAIDs, effective preventive and treatment strategies are crucial. We assessed the effect of tegoprazan on NSAID-induced enteropathy. Human epithelial cells (HIEC-6, HT-29, and Caco-2) were treated with indomethacin and tegoprazan. Cell viability, expression levels of tight-junction proteins, levels of proinflammatory cytokines, and apoptosis were assessed by conducting MTT assays, RT-PCR, western blotting, and immunofluorescence staining, respectively. Tegoprazan significantly ameliorated the inhibition of cell proliferation induced by indomethacin. Tegoprazan also mitigated the suppression of occludin and ZO-1 expression by indomethacin, thereby restoring intestinal permeability. Additionally, tegoprazan reversed the indomethacin-induced elevation of the levels of proinflammatory cytokines and the rate of apoptosis of small intestinal epithelial cells. Our findings indicate that tegoprazan exerts a protective effect against NSAID-induced injury to small intestinal epithelial cells. The effect involves enhancement of the expression levels of tight junction proteins and the suppression of inflammation and apoptosis. |
| format | Article |
| id | doaj-art-b731d63aa2014725b0b864bf640f7e78 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-b731d63aa2014725b0b864bf640f7e782025-08-20T02:50:00ZengNature PortfolioScientific Reports2045-23222024-11-0114111010.1038/s41598-024-78581-2Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathyHyun Jung Lee0Ji Wook Moon1Seong-Joon Koh2Jong Pil Im3Byeong Gwan Kim4Joo Sung Kim5Department of Internal Medicine and Liver Research Institute, Seoul National University College of MedicineBK21 Graduate Program, Department of Biomedical Sciences, Department of Anatomy, Korea University College of MedicineDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of MedicineDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of MedicineDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of MedicineDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of MedicineAbstract As the non-steroidal anti-inflammatory drugs (NSAIDs) are typically used in the treatment of chronic conditions, the incidence of NSAID-induced enteropathy is increasing. Given the challenges associated with discontinuing NSAIDs, effective preventive and treatment strategies are crucial. We assessed the effect of tegoprazan on NSAID-induced enteropathy. Human epithelial cells (HIEC-6, HT-29, and Caco-2) were treated with indomethacin and tegoprazan. Cell viability, expression levels of tight-junction proteins, levels of proinflammatory cytokines, and apoptosis were assessed by conducting MTT assays, RT-PCR, western blotting, and immunofluorescence staining, respectively. Tegoprazan significantly ameliorated the inhibition of cell proliferation induced by indomethacin. Tegoprazan also mitigated the suppression of occludin and ZO-1 expression by indomethacin, thereby restoring intestinal permeability. Additionally, tegoprazan reversed the indomethacin-induced elevation of the levels of proinflammatory cytokines and the rate of apoptosis of small intestinal epithelial cells. Our findings indicate that tegoprazan exerts a protective effect against NSAID-induced injury to small intestinal epithelial cells. The effect involves enhancement of the expression levels of tight junction proteins and the suppression of inflammation and apoptosis.https://doi.org/10.1038/s41598-024-78581-2Non-steroidal anti-inflammatory drugEnteropathyTegoprazanPermeability |
| spellingShingle | Hyun Jung Lee Ji Wook Moon Seong-Joon Koh Jong Pil Im Byeong Gwan Kim Joo Sung Kim Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy Scientific Reports Non-steroidal anti-inflammatory drug Enteropathy Tegoprazan Permeability |
| title | Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy |
| title_full | Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy |
| title_fullStr | Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy |
| title_full_unstemmed | Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy |
| title_short | Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy |
| title_sort | effect of tegoprazan a novel potassium competitive acid blocker on non steroidal anti inflammatory drug nsaid induced enteropathy |
| topic | Non-steroidal anti-inflammatory drug Enteropathy Tegoprazan Permeability |
| url | https://doi.org/10.1038/s41598-024-78581-2 |
| work_keys_str_mv | AT hyunjunglee effectoftegoprazananovelpotassiumcompetitiveacidblockeronnonsteroidalantiinflammatorydrugnsaidinducedenteropathy AT jiwookmoon effectoftegoprazananovelpotassiumcompetitiveacidblockeronnonsteroidalantiinflammatorydrugnsaidinducedenteropathy AT seongjoonkoh effectoftegoprazananovelpotassiumcompetitiveacidblockeronnonsteroidalantiinflammatorydrugnsaidinducedenteropathy AT jongpilim effectoftegoprazananovelpotassiumcompetitiveacidblockeronnonsteroidalantiinflammatorydrugnsaidinducedenteropathy AT byeonggwankim effectoftegoprazananovelpotassiumcompetitiveacidblockeronnonsteroidalantiinflammatorydrugnsaidinducedenteropathy AT joosungkim effectoftegoprazananovelpotassiumcompetitiveacidblockeronnonsteroidalantiinflammatorydrugnsaidinducedenteropathy |